HER2 status changes dynamically during treatment, with 66% of patients showing concordant HER2 status between primary and metastatic lesions, and a 9.7% conversion rate from HER2-negative to HER2-positive in metastatic tumors [68]. This evidence concerns the gene ERBB2 and metastatic neoplasm.